SCHEMBL6312155

SCHEMBL6312155

CCc1ccc(Nc2ncc(-c3cnc4ccccc4c3)c(N)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.46
NPC1 O15118 5/20 0.46
PTK2 Q05397 1/20 0.46
KDM4E B2RXH2 2/20 0.43
STK17B O94768 1/20 0.43
STK17A Q9UEE5 1/20 0.43
STAT1 P42224 1/20 0.43
KMT2A Q03164 2/20 0.41
PKM P14618 2/20 0.41
KDM1A O60341 1/20 0.40
IGF1R P08069 1/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PIK3C3 Q8NEB9 1/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312636 0.90 CDK5 (0.47) RAB9ANPC1PTK2KDM4EKMT2A
SCHEMBL6311942 0.88 DYRK1A (0.43) RAB9ANPC1KDM4ESTK17BSTK17A
SCHEMBL6312806 0.86 IGF1R (0.47) IGF1RNPSR1PIK3C3CYP2A6DHFR
SCHEMBL6318900 0.84 IGF1R (0.58) RAB9ANPC1KMT2AIGF1RALDH1A1
SCHEMBL6312956 0.83 IGF1R (0.45) RAB9ANPC1PTK2KMT2APKM
SCHEMBL6312020 0.81 SYK (0.47) RAB9ANPC1KDM4EKMT2AIGF1R
SCHEMBL6311735 0.81 CTSC (0.50) RAB9ANPC1KMT2AIGF1RMAPT
SCHEMBL6312590 0.81 IGF1R (0.58) IGF1RLMNASMN1; SMN2DHFR
SCHEMBL6312056 0.80 IGF1R (0.60) KMT2AIGF1RMEN1
SCHEMBL6314422 0.79 IGF1R (0.60) KMT2AIGF1RALDH1A1TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939874-B2 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. (US) 2005-09-06 US claimed
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. 2004-04-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use DPYD, TYMP, TPMT RAB9A 2743/4885NPC1 473/4885PTK2 3457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.